<?xml version='1.0' encoding='utf-8'?>
<document id="27317415"><sentence text="Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors." /><sentence text="Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) are members of the latest class of antiretrovirals (ARVs) that have become available to treat human immunodeficiency virus (HIV) infection: integrase strand transfer inhibitors (INSTIs)"><entity charOffset="0-12" id="DDI-PubMed.27317415.s2.e0" text="Dolutegravir" /><entity charOffset="14-17" id="DDI-PubMed.27317415.s2.e1" text="DTG" /><entity charOffset="20-32" id="DDI-PubMed.27317415.s2.e2" text="elvitegravir" /><entity charOffset="34-37" id="DDI-PubMed.27317415.s2.e3" text="EVG" /><entity charOffset="43-54" id="DDI-PubMed.27317415.s2.e4" text="raltegravir" /><entity charOffset="56-59" id="DDI-PubMed.27317415.s2.e5" text="RAL" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e0" e2="DDI-PubMed.27317415.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e1" e2="DDI-PubMed.27317415.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e1" e2="DDI-PubMed.27317415.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e1" e2="DDI-PubMed.27317415.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e1" e2="DDI-PubMed.27317415.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e1" e2="DDI-PubMed.27317415.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e2" e2="DDI-PubMed.27317415.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e2" e2="DDI-PubMed.27317415.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e2" e2="DDI-PubMed.27317415.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e2" e2="DDI-PubMed.27317415.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e3" e2="DDI-PubMed.27317415.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e3" e2="DDI-PubMed.27317415.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e3" e2="DDI-PubMed.27317415.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e4" e2="DDI-PubMed.27317415.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317415.s2.e4" e2="DDI-PubMed.27317415.s2.e5" /></sentence><sentence text=" INSTIs are potent inhibitors of the HIV integrase enzyme, with protein binding-adjusted concentration inhibiting viral replication by 90/95 % [IC90/95] values in the low nanogram per millilitre range, and they retain antiviral activity against strains of HIV with acquired resistance to other classes of ARVs" /><sentence text=" Each of the INSTIs has unique pharmacokinetic/pharmacodynamic properties, influencing its role in clinical use in specific subsets of patients" /><sentence text=" RAL and DTG have minimal drug-drug interaction profiles, as their metabolism has minimal cytochrome P450 (CYP) involvement"><entity charOffset="9-11" id="DDI-PubMed.27317415.s5.e0" text="DTG" /><entity charOffset="1-3" id="DDI-PubMed.27317415.s5.e1" text="RAL" /><pair ddi="false" e1="DDI-PubMed.27317415.s5.e1" e2="DDI-PubMed.27317415.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27317415.s5.e1" e2="DDI-PubMed.27317415.s5.e0" /></sentence><sentence text=" Conversely, EVG metabolism occurs primarily via CYP3A4 and requires pharmacokinetic boosting to achieve systemic exposures amenable to once-daily dosing"><entity charOffset="13-15" id="DDI-PubMed.27317415.s6.e0" text="EVG" /></sentence><sentence text=" EVG and DTG have the added benefit of availability of fixed-dose combination tablets, allowing for convenient and simplified ARV regimens"><entity charOffset="9-11" id="DDI-PubMed.27317415.s7.e0" text="DTG" /><entity charOffset="1-3" id="DDI-PubMed.27317415.s7.e1" text="EVG" /><pair ddi="false" e1="DDI-PubMed.27317415.s7.e1" e2="DDI-PubMed.27317415.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27317415.s7.e1" e2="DDI-PubMed.27317415.s7.e0" /></sentence><sentence text=" RAL is the only INSTI to be listed as a preferred agent in the current US perinatal treatment guidelines"><entity charOffset="1-3" id="DDI-PubMed.27317415.s8.e0" text="RAL" /></sentence><sentence text=" All three INSTIs are recommended regimens for treatment-naïve individuals in the US adult and adolescent HIV treatment guidelines" /><sentence text=" This review summarizes and compares the pharmacokinetics and pharmacodynamics of the INSTIs, and describes specific pharmacokinetic considerations for special patient conditions: hepatic impairment, renal dysfunction, pregnancy and co-infections" /><sentence text="" /></document>